Cargando…

Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor – A case report

Dipeptidyl peptidase-4 inhibitors (DPP-4i) are one of the mainstay drugs in the management of type 2 diabetes mellitus. It has been well-documented that these class of drugs cause allergic reactions. Bullous pemphigoid (BP) is a blistering skin condition commonly associated with many drugs. Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karthik, S, Joseph, PE, Babu, T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813680/ https://www.ncbi.nlm.nih.gov/pubmed/31535624 http://dx.doi.org/10.4103/jpgm.JPGM_120_19

Ejemplares similares

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
por: Tasanen, Kaisa, et al.
Publicado: (2019)

Bullous pemphigoid associated with use of dipeptidyl peptidase-4 inhibitor
por: Kano, Yasuhiro, et al.
Publicado: (2022)

Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid()()
por: Gravani, Agoritsa, et al.
Publicado: (2021)

Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitors: A report of five cases
por: Yoshiji, Satoshi, et al.
Publicado: (2017)

Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology
por: Murakami, Takaaki, et al.
Publicado: (2019)

Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication
por: Shinohara, Yasutake, et al.
Publicado: (2020)

Dipeptidyl Peptidase-4 Inhibitors Cause Bullous Pemphigoid in Diabetic Patients: Report of Two Cases
por: Pasmatzi, Efi, et al.
Publicado: (2011)

Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients
por: Balighi, Kamran, et al.
Publicado: (2022)

Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid
por: Kinyó, Ágnes, et al.
Publicado: (2021)

Bullous Pemphigoid Associated with the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin in a Patient with Liver Cirrhosis Complicated with Rapidly Progressive Hepatocellular Carcinoma
por: Harada, Masaru, et al.
Publicado: (2017)

The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study
por: Lambadiari, Vaia, et al.
Publicado: (2021)

Ocular cicatricial pemphigoid following Dipeptidyl Peptidase-4 inhibitor use: A case report
por: Matsumoto, Akifumi, et al.
Publicado: (2023)

Clinical Features and Outcomes of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid (DPP4i-Associated BP) in Thai Patients
por: Thewjitcharoen, Yotsapon, et al.
Publicado: (2020)

Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
por: Iwamoto, Yuichiro, et al.
Publicado: (2022)

Dipeptidyl peptidase‐4 inhibitors‐associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients
por: Kawaguchi, Yohei, et al.
Publicado: (2018)

Dipeptidyl Peptidase-4 Inhibitor-Related Bullous Pemphigoid: Clinical, Laboratory, and Histological Features, and Possible Pathogenesis
por: Hung, Chih-Tsung, et al.
Publicado: (2022)

Lisinopril prevents bullous pemphigoid induced by dipeptidyl peptidase 4 inhibitors via the Mas receptor pathway
por: Nozawa, Keisuke, et al.
Publicado: (2023)

Serum autoantibodies against the extracellular region of α6β4 integrin in a patient with dipeptidyl peptidase-4 inhibitor–induced bullous pemphigoid
por: Yamashita, Chigusa, et al.
Publicado: (2021)

The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study
por: Bukvić Mokos, Zrinka, et al.
Publicado: (2020)

Bullous Pemphigoid Associated with Dipeptidyl Peptidase 4 Inhibitors for the Treatment of Type 2 Diabetes: A Multicenter Study in Istanbul
por: Ugurer, Ece, et al.
Publicado: (2022)

Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180
por: Mai, Yosuke, et al.
Publicado: (2019)

Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature
por: Mai, Yosuke, et al.
Publicado: (2018)

SARS‐CoV‐2 vaccine‐triggered conversion from systemic lupus erythematosus (SLE) to bullous SLE and dipeptidyl peptidase 4 inhibitors‐associated bullous pemphigoid
por: Nakahara, Yukiko, et al.
Publicado: (2022)

Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation
por: Kridin, Khalaf, et al.
Publicado: (2022)

Pemphigoid Nodularis Induced by Long-Term Use of Dipeptidyl Peptidase-4 Inhibitors
por: Norikawa, Natsumi, et al.
Publicado: (2023)

Tozinameran: Bullous pemphigoid: case report
Publicado: (2022)

Tozinameran: Bullous pemphigoid: case report
Publicado: (2022)

Tozinameran: Bullous pemphigoid: case report
Publicado: (2022)

Tozinameran: Bullous pemphigoid: case report
Publicado: (2022)

Tozinameran: Bullous pemphigoid: case report
Publicado: (2022)

Bullous pemphigoid associated with nintedanib
por: Hasson, Amelia M., et al.
Publicado: (2019)

Semaglutide-associated bullous pemphigoid
por: Burruss, Clayton P., et al.
Publicado: (2021)

Collagenous Colitis Possibly Associated with Dipeptidyl Peptidase-4 Inhibitor
por: Takedomi, Hironobu, et al.
Publicado: (2022)

Localized bullous pemphigoid: a case report
por: Wang, Yiman, et al.
Publicado: (2020)

Azd-1222: Bullous pemphigoid: case report
Publicado: (2022)

Bullous Pemphigoid Associated with Erythrodermic Psoriasis: A Case Report
por: Chen, Wenjuan, et al.
Publicado: (2022)

More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study
por: Ständer, Sascha, et al.
Publicado: (2020)

Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib
por: Nash, David, et al.
Publicado: (2022)

Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase‐4 inhibitors: A population‐based cohort study using Japanese Latter‐Stage Elderly Healthcare Database
por: Harano, Yumi, et al.
Publicado: (2023)

Bullous pemphigoid associated with the use of dipeptidil peptidase-4 inhibitors: analysis from studies based on pharmacovigilance databases
por: Molina-Guarneros, Juan A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vnidrd0gv3k9hr8503f7h53cg8